Advertisement


Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the data to date on checkpoint blockades and the rationale for combination therapies and novel agents.



Related Videos

Breast Cancer
Immunotherapy

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Building on Recent Successes

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute, discusses the encouraging data on atezolizumab plus nab-paclitaxel in the first-line setting for metastatic...

Immunotherapy

Kim A. Margolin, MD, on Promising Immunotherapy Strategies

Kim A. Margolin, MD, of the University of California, Los Angeles Harbor Medical Center, summarizes a session she co-chaired on combination immunotherapies, locoregional ther...

Lung Cancer
Immunotherapy

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Edward B. Garon, MD, of the Olive View–UCLA Medical Center, discusses phase IIIb/IV study findings on reducing the frequency of nivolumab dosing, from 480 mg every 4 weeks to...

Lung Cancer
Immunotherapy

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Predicting Response to PD-1 Inhibitors With cfDNA

Nicolas Guibert, MD, PhD, of Toulouse University Hospital, discusses a simple algorithm built to predict durable outcomes of patients with advanced non–small cell lung cancer...

Leukemia
Immunotherapy

Stefan O. Ciurea, MD, on Infusing High Doses of Natural Killer Cells: An Enhanced Antitumor Effect

Stefan O. Ciurea, MD, of The University of Texas MD Anderson Cancer Center, discusses the enhanced antitumor effect and lower viral reactivation that result from high doses of natu...

Advertisement

Advertisement



;
Advertisement